Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

BTMD - biote Corp. Последние новости | Finranks

Home

BTMD

(BTMD)

NGM – Цена в реальном времени. Валюта: USD

1.32

-0.03 (-2.22%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

1.33

+0.01 (1.11%)

После закрытия: Mar 27, 2026, 7:31 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Видео

No Data

There is no data to display

Пресс-релизы

Biote Reports Fourth Quarter and Full Year 2025 Financial Results

Biote Reports Fourth Quarter and Full Year 2025 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. “Over the past twelve months, Biote has focused on our strategic priorities which are designed to drive sustainable profitable growth and create long-term value for stockholders,” said Bret Christensen, Biote's Chief.

Biote Reports Third Quarter 2025 Financial Results

Biote Reports Third Quarter 2025 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the third quarter ended September 30, 2025. “When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate growth from new providers, maximize value from our top-tier clinics, and improve our financial performance through gre.

Biote Reports Second Quarter 2025 Financial Results

Biote Reports Second Quarter 2025 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2025. “Consistent with our action plan to drive structural and cultural change, Biote initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable.